RiskReaper
@RiskReaper10
Followers
120
Following
170
Media
17
Statuses
227
Patience prints money
United States Rochester, MN
Joined November 2023
$SPY Put Volume jumped to the 2nd highest reading ever! Previous spikes were near bottoms for the S&P 500
61
315
1K
Multi-cancer expansion potential alone can justify a $50-100M valuation floor. If acquisition chatter is real, that floor becomes the starting point. #sstvi #MissUniverse2025 $NOK $SPY
🔥 BUYOUT BUZZ GOING CRAZY - I’M NOT SITTING THIS ONE OUT Bro, I wasn’t even planning to touch $MYNZ today, but this buyout chatter from a big diagnostics name is hitting different. And honestly? It makes PERFECT sense. Look at what MYNZ’s packing: A pancreatic test with 100%
0
0
0
Low-float bios with billion-dollar addressable problems are prime squeeze candidates. If $MYNZ flow spikes above 1-2M consistently, the path to teens gets mechanical. $ONDS #sstvi $AMC $MSFT
$MYNZ 🚨 EXTREME FLOW ALERT Early detection in pancreatic cancer is a billion-dollar problem with almost no winners. Mainz Biomed showing strong early accuracy puts them in a strategic sweet spot. If the trajectory holds, this can naturally climb toward low-to-mid teens. Not
0
0
0
$IREN (weekly) — Anything between here and $30 seems like a great deal to me, as I do see this one reaching $70 again. Analyst price targets sit at $70.89, and with that massive Microsoft AI cloud deal in the books, the runway's there. Structure's solid—this pullback's just
7
18
131
Trading at barely 1x potential future revenue while peers trade at 4-6x sets up a structural imbalance. $MYNZ needs only modest commercial traction to justify a 200-300% markup. $BMNR #sstvi $ACHR
$MYNZ is being accumulated under the radar, and the clearest proof is Armistice moving its position to 9.99 percent. This is not noise; funds do not take positions this large in companies they consider fairly valued. With near-perfect pancreatic cancer pilot results,
0
0
0
Structural undervaluation plus institutional confirmation is the combo that often produces outsized upside. $MYNZ looks like it’s entering that sweet spot $PYPL #sstvi $TSLA $AMZN
$MYNZ is structurally undervalued when a catalyst-driven hedge fund like Armistice pushes ownership to 9.99%, expanding by over 40% in one filing cycle. That kind of accumulation rarely occurs without expectation of a rerate. With world-class diagnostic accuracy and new LATAM
0
0
0
If this happens - A lot of people are going to lose their shit. Literally $NVDA
50
19
264
S&P 500 $SPY has gone from a 2% breakout to below 6,600. Market having a bit of a tantrum with no December cut.
4
9
48
$MYNZ This kind of clinical strength usually forces a valuation reset. I’m early. #sstvi $AMD $CODX $COF
$MYNZ remains one of the most mispriced biotech plays in the microcap universe. When Armistice takes a 9.99% stake, that signals conviction, not speculation. Add ColoAlert’s 97 percent detection rate, 80 percent adenoma accuracy and near-perfect PancAlert pilot results and this
0
0
1
$INTC Vanguard Group purchased 16.8 million Intel shares in the first half of the year. The total for the third quarter was 390 million shares. These guys are just buying
0
0
2
$MYNZ A 9.99 percent institutional position at this stage is basically a vote of confidence on future pricing - and the chart hasn’t even reacted properly yet. $ARVN $F $QCOM $MSFT #GranHermano #BBB25
$MYNZ is entering a phase where undervaluation becomes impossible to justify. Armistice Capital now holds 324,821 shares, representing 9.99 percent ownership, after increasing its stake by 40.64 percent. Institutions do not take 10 percent positions in random microcaps. With
0
0
1
Still holding my $SPY short. I’ve got headroom to my stop and made the decision to play for a bigger move. The trade is now breakeven or better, so there’s no downside if I’m wrong. I don’t believe $NVDA’s earnings magically repaired the technical damage overnight That said,
minervini.com
Minervini Markets 360 is the ultimate trading platform developed by U.S. Investing Champion Mark Minervini. Access powerful, battle-tested tools, real-time portfolio management, proprietary indicat...
I shorted $SPY on Wednesday. The long-term trend remains up, but breadth is weakening — fewer stocks above their 50-day lines; a divergence that has been worsening for months. Rate cuts are priced in, and with the Fed hinting at a pause, a pullback looks likely.
132
202
2K
Another day in the books 🔥 These $QQQ 605p are sitting at over 1000% right now 🤯
16
7
207
Momentum on $NXXT feels like the start of a bigger leg. When an industry with 50,000+ facilities needs microgrids, early movers win big. #HealthcareMicrogrid #sstvi $DHR $AAPL
You will see NASDAQ NXXT breaking $3 Why ? U.S. healthcare spends $4.9T/year and runs over 50,000+ critical-care facilities (hospitals, nursing homes, assisted living). That entire machine dies in minutes without power. You don’t think microgrids will be a core part of this?
0
0
0
Pullbacks on $NXXT look more like liquidity gifts than weakness. Macro noise hit sentiment, but the company’s R/R just improved. $ONDS $DNN $VNDA $ECL #WWERAW
Smart Money Buys Fear, Not FOMO Yeah dollar ripping, indexes wobbling… classic risk-off rotation. But $NXXT fundamentals = untouched: +230% YoY, sector-lowest multiple, insane R/R at these levels. This is the window where pros DCA before the next MOVE. Target stays $5.20–5.60
0
0
0